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Importantly, the findings of Derksen 
et al. constitute the first demonstration in 
mice of a causal link between E-cadherin 
loss and tumor formation. Given the 
wealth of data from cell culture studies 
and human patient samples implicating 
E-cadherin in tumor progression, this is 
a central finding that establishes E-cad-
herin as a bona fide tumor suppressor. 
Notably, while E-cadherin loss is thought 
to be a critical step in the process of 
epithelial-to-mesenchymal transition 
(EMT), the extent to which EMT per se 
is involved in tumor progression remains 
unclear. For example, the transcription-
al repressor Snail has been shown to 
downregulate E-cadherin as well as pro-
mote both EMT and tumor progression 
in a conditional mouse model for HER2/
neu-induced breast cancer (Moody et 
al., 2005). In contrast, E-cadherin loss 
in the model described by Derksen et al. 
does not by itself lead to a frank mesen-
chymal phenotype. This suggests that, at 
least in this context, E-cadherin loss can 
promote tumorigenesis independently of 
its contribution to EMT.
Another puzzling feature of this dis-
ease has been the uncertain relationship 
between ILC and lobular carcinoma in 
situ (LCIS). Women with LCIS are at sub-
stantially increased risk for developing 
breast cancer both in the same breast 
in which the LCIS was identified and in 
the opposite breast. As such, whether 
LCIS represents a precursor lesion to 
ILC, or merely a marker of increased 
risk, continues to be a matter of debate. 
It is notable, therefore, that despite the 
markedly increased risk of mILC in mice 
in which E-cadherin and p53 have been 
deleted in the mammary epithelium, 
classic LCIS lesions are not found. This 
raises the important possibility that LCIS 
is not a precursor lesion for ILC, or that 
mILC models a form of ILC that does not 
pass through an LCIS phase.
Finally, beyond its important 
mechanistic implications, this study by 
Derksen et al. is equally significant for 
its establishment of a faithful model for 
human ILC where none existed before. 
This accomplishment represents a 
significant step forward in the effort 
to accurately model human cancers in 
mice. As they constitute only 10%–15% 
of all breast cancers, lobular carcino-
mas are likely to differ from ductal 
carcinomas with respect to their etiol-
ogy, biology, and response to therapy. 
As such, the availability of this model 
holds significant promise for improving 
our ability to understand and treat this 
type of breast cancer. Undoubtedly, it 
will be important to continue refining 
this model to more precisely incorpo-
rate the molecular alterations found 
in human ILC, as these become eluci-
dated. Ultimately, such models should 
prove useful for testing therapeutic reg-
imens targeted specifically against ILC 
and in that manner improve the clinical 
management of this disease. This hope, 
if realized, would constitute the most 
meaningful validation of all for this—or 
any—mouse model.
James v. Alvarez,1 Denise Perez,1 
and Lewis A. Chodosh1,*
1Department of Cancer biology and 
Abramson Family Cancer research 
Institute, University of Pennsylvania 
School of medicine, Philadelphia, 
Pennsylvania 19104 
*e-mail: chodosh@mail.med.upenn.edu
Selected reading
Arpino, G., Bardou, V.J., Clark, G.M., and Elledge, 
R.M. (2004). Breast Cancer Res. 6, R149–R156.
Derksen, P.W.B., Liu, X., Saridin, F., van der 
Gulden, H., Zevenhoven, J., Evers, B., van 
Beijnum, J.R., Griffioen, A.W., Vink, J., and 
Krimpenfort, P. (2006). Cancer Cell, this issue.
Holland, E.C. (2004). Mouse Models of Human 
Cancer (Hoboken, N.J.: Wiley-Liss).
Mohsin, S.K., O’Connell, P., Allred, D.C., and 
Libby, A.L. (2005). Breast Cancer Res. Treat. 90, 
249–256.
Moody, S.E., Perez, D., Pan, T.C., Sarkisian, C.J., 
Portocarrero, C.P., Sterner, C.J., Notorfrancesco, 
K.L., Cardiff, R.D., and Chodosh, L.A. (2005). 
Cancer Cell 8, 197–209.
Papadimitriou, C.S., Costopoulos, J.S., 
Christoforidou, B.P., Kotsianti, A.J., Karkavelas, 
G.S., Hytiroglou, P.M., Koufogiannis, D.J., and 
Nenopoulou, H.E. (1997). Eur. J. Cancer 33, 
1275–1280.
Sharpless, N.E., and Depinho, R.A. (2006). Nat. 
Rev. Drug Discov. 5, 741–754.
Stange, D.E., Radlwimmer, B., Schubert, F., Traub, 
F., Pich, A., Toedt, G., Mendrzyk, F., Lehmann, U., 
Eils, R., Kreipe, H., and Lichter, P. (2006). Clin. 
Cancer Res. 12, 345–352.
DOI 10.1016/j.ccr.2006.10.016Accelerating drug discovery: Open source cancer cell biology?
The possibility that experimental data from diverse cell biology experiments might shed light on other experiments has been 
generally outside the realm of cancer biologists. Recent experiments suggest that core RNA expression profiles distilled from 
experiments using a set of known members with related attributes may be used as query tools to probe expression profiles from 
other unrelated experiments. The potential benefit arises from the possibility to share findings without fully reconstructing the 
exact initial conditions. The limitations will be framed by the robustness of the hypotheses so generated.As one looks back over past decades, or 
for that matter, past centuries, scientific 
progress, though remarkable, has been 
limited by tools and the ways insights 
have been shared. Three recent papers 
by the Golub and Armstrong groups 
(Lamb et al., 2006; Hieronymus et al., 
cancer cell November 2006 2006; Wei et al., 2006) describe a pro-
cess, a tool, and even better, examples 
of how that tool functions that suggest 
an opportunity which, if fully implement-
ed, has the potential to truly change the 
speed and efficiency of drug discovery.
One of the rather hidden inadequa-cies of cancer biology and drug discov-
ery is the full extent to which we fly blind. 
From the size of textbooks and the com-
plexity of pathway diagrams it is hard 
to recognize that for virtually all cancer 
processes we do not have confidence in 
the complete “parts list” of components 349
	 p r e v i e w sFigure 1. Using a gene expression pattern for the “Connectivity map”
Cells are treated with diverse molecular compounds (or genetic perturbations), and gene expression 
patterns are stored in the database. A “signature of interest” derived from a disease type (for example, 
obese versus normal, or drug resistant versus sensitive) can be used to query the database to find which 
compound or drug treatment could reverse the pattern. A “signature of interest” could also be from a 
novel compound. The target pathways of this novel compound can be elucidated by pattern match-
ing to the compounds or drugs in the database with known targets or functions.for these pathways, let alone their cross-
wiring diagrams. There is, however, a 
more fundamental and critical problem, 
and that is the way cancer biologists 
have until now shared their data.
Here, we do not refer to the preva-
lent data sets in the silos of intellectual 
property-driven universities or even the 
more striking company silos. Instead, 
we are referring to what happens to 
the data sets at the end of any biologi-
cal experiment. Most often, it is simply 
thrown away. In a fashion that would be 
deplored by environmentalists, cancer 
biologists do not readily recycle the data 
sets because we can’t. For today’s cel-
lular biology experiment, the primary 
light of day is in the hallowed realm of 
publications, where the sections appear 
as follows: title, data, methods, and con-
clusions. Our concern is that the ability 
to leverage this information is primarily 
limited by the need to reconstruct that 
specific set of conditions to truly extend 
the finding. To point out this inefficiency, 
we need only refer to software engi-
neers. One could argue that the most 
exciting development in the software 
field is not the benefit properly attrib-
uted to the engineers and their creations 
that drive Moore’s law (Moore, 1965), 350 but the open source strategies driven 
originally by Richard Stallman (see, for 
example, http://www.opensource.org/). 
The excitement regarding open source 
approaches arises from the power of 
having computer science’s currency of 
discovery, lines of code, increasingly 
made accessible and, more importantly, 
evolved by many people. As biologists, 
we have marveled with sheer jealousy 
at how efficient this sharing of discovery 
can be. To understand how the papers 
by Golub, Armstrong, and colleagues 
may potentially help release this data 
set segmentation problem in biology, it 
is necessary to describe what they have 
done. These papers suggest a novel way 
to share the data sets generated within 
experiments.
In a recent issue of Science, Golub 
and coworkers published a striking 
paper about a “Connectivity Map” for a 
mammalian system (Lamb et al., 2006). 
They treated the cells with a collection 
of diverse small-molecule compounds, 
recorded gene expression alterations 
caused by each of the compounds, 
stored these expression patterns in the 
database, and then used the pattern 
matching method to link up the com-
pounds of unknown function with com-pounds with known biological targets 
and functions (see Figure 1). In addi-
tion, they show that this same database 
can be used to find new therapeutics 
that can reverse a disease pattern. Two 
applications for this Connectivity Map 
are fully illustrated by the papers in 
Cancer Cell (Hieronymus et al., 2006; 
Wei et al., 2006).
In the first paper, Wei et al. tackle the 
phenomenon of drug resistance, a major 
obstacle to successful cancer treatment. 
Armstrong and coworkers first identified 
a gene expression pattern associated 
with resistance to dexamethasone treat-
ment in primary acute lymphoblastic leu-
kemia (ALL) cells and, by the use of a 
Connectivity Map, they identified that a 
marketed drug, rapamycin, can reverse 
the resistance pattern (Wei et al., 2006). 
They thus hypothesized that rapamycin 
would induce dexamethasone sensitivity 
in lymphoid malignancy cells and found 
that it indeed sensitized the resistant 
lymphoid cell line to dexamethasone-
induced apoptosis via a modulation of 
antiapoptotic protein MCL-1. This result 
suggests that dexamethasone in com-
bination with rapamycin could be an 
effective therapy for childhood ALL and 
should be tested immediately in clinical 
trials.
In the second example, Golub and 
coworkers demonstrated the power of 
gene expression-based high-through-
put screening for identifying novel 
compounds and used a Connectivity 
Map to elucidate the target pathways 
(Hieronymus et al., 2006). The andro-
gen receptor (AR)-mediated pathway 
that they explored is associated with 
prostate cancer progression and even-
tual hormonal therapy resistance, but 
the ability to modulate this pathway is 
limited. Using a defined AR activation 
gene signature in a prostate cell line and 
bead-based expression platform, they 
identified celestrol and gedunin from 
2500 compounds as novel inhibitors for 
the AR signaling pathway. Then, using 
the “Connectivity Map,” they showed 
that the modulation of AR pathway acted 
through an upstream HSP90 pathway.
Considering that the first publica-
tion of a yeast compendium of geneti-
cally altered organisms, conditions, 
and compounds describing the benefits 
of using knowns to query unknowns 
was published in 2000 (Hughes et al., 
2000), why did it take more than 5 years 
to generate a counterpart in mammalian cancer cell November 2006
	 p r e v i e w scells? First, there has been a common 
fear that a mammalian system would be 
intrinsically complex compared to the 
yeast. Apart from shared problems like 
dose and time of treatment, there are 
many extra hurdles in the mammalian 
system, such as the complexity result-
ing from many cell types, many tissues, 
in vitro and in vivo, tumor and normal, 
individual variability, etc. Furthermore, 
many groups became stuck at the stage 
of discussing which cell to choose to 
construct a compound expression com-
pendium. Current results by Golub and 
Armstrong et al. suggest that a big frac-
tion of connectivity appears to be to a 
large extent cell line independent. They 
even include examples that suggest 
connectivity across species, and from 
in vitro to in vivo (obesity example from 
Lamb et al., 2006). The second reason 
could be the inadequacies of existing 
analytical methods. Previous attempts 
were more or less limited to the genome-
wide comparison, like hierarchical clus-
tering, which has limited sensitivity and 
specificity. The approach used by Golub 
and coworkers focuses on the “signa-
ture of interest,” like a gene set related 
to disease, or a gene set related to drug 
resistance. Knowing how to define a 
gene signature set is also a key factor to 
success. The rank-based method used 
by the authors also helps them query 
the patterns across multiple platforms.
Does this mean that having a 
Connectivity Map is equivalent to hav-
ing the final answer? No. We are still far 
away from that, and it probably will never 
be the case. The Connectivity Map will 
help us to generate hypotheses and to 
guide our next cell- or lab-based experi-
ments to test these hypotheses, like the 
authors showed in their examples. Take 
the drug resistance case—we still do 
not have a “home run.” The intermedi-
ate results (based on the cell models in 
the lab) look encouraging, but the final 
test will be clinical trials based on these 
hypotheses. At least now, with this tool, 
we are not as “blinded” as before.
There is also some distance 
between identifying target pathways and 
identifying the true target. The HSP90 cancer cell November 2006 example showed that the compounds 
modulated this pathway to regulate the 
AR-mediated signaling, but work, prob-
ably a significant amount, still remains to 
identify the target protein in the HSP90 
pathway.
These approaches and applications 
are strong, but why did we chose in the 
introduction to use the phrase “potential 
to truly change the speed and efficiency 
of drug discovery”? This goes back to 
the initial descriptions of sharing data. 
The power of the Connectivity Map 
described by Golub et al. is that it has 
been built so that it is driven by the use 
of signatures as the query tool. By dis-
tilling a core signature out of an experi-
ment involving a set of compounds or 
conditions, as opposed to searching 
the entire signature against other sig-
natures in a critical way, the robustness 
of the signature apparently frequently 
increases to where it can be used to 
link experiments that have not all been 
done under identical conditions. The 
power stems from the fact that unre-
lated experiments might potentially be 
queried for their component parts, and 
even better, be queried in the future as 
new questions and data sets are gener-
ated such that the opportunity for open 
source cell biology can be considered. 
Work done by Schadt et al. suggests 
that using core signatures may also be 
a tool for exploring causality in map-
ping cellular pathways (Schadt et al., 
2005). Both these methods, of course, 
apply not just to cancer biology but more 
broadly. The long-term benefits of the 
Connectivity Maps, therefore, may be 
that signatures be they RNA-based or 
protein-based become the currency that 
empowers biological scientists to recy-
cle their data and to share and build on 
it in an open architecture context.
Is it premature to declare the utility of 
the end state? Here again, we biologists 
should take a page out of the software 
engineer’s rule book and declare that 
this is just version 1.0. Is it worth the NIH 
investing in the next version? You bet. Is it 
worth involving the FDA and companies? 
You bet. So that expectations aren’t inad-
vertently set too high and later crashed, here is an opportunity for groups to work 
together as partners. Here is a chance to 
define together the appropriate scope for 
version 2.0, be it around a compendium 
of all FDA drugs, or tackling the safety 
and efficacy of emerging treatments in a 
critical path initiative, or even potentially 
focusing on a treatment modality that 
could speed a specific treatment oppor-
tunity such as prostate cancer. Each of 
these would be large projects where 
the synergy would be maximized if aca-
demia, industry, and government efforts 
were able to be linked.
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